Last reviewed · How we verify
DYV700
DYV700 is a small molecule inhibitor of the CDK9 enzyme.
DYV700 is a small molecule inhibitor of the CDK9 enzyme. Used for Relapsed or refractory acute myeloid leukemia.
At a glance
| Generic name | DYV700 |
|---|---|
| Sponsor | Dyve Biosciences, Inc. |
| Drug class | CDK inhibitor |
| Target | CDK9 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting CDK9, DYV700 reduces the phosphorylation of RNA polymerase II, leading to a decrease in mRNA transcription and subsequent reduction in protein synthesis. This mechanism is particularly relevant in the treatment of cancer, where uncontrolled cell growth is a hallmark of the disease.
Approved indications
- Relapsed or refractory acute myeloid leukemia
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DYV700 CI brief — competitive landscape report
- DYV700 updates RSS · CI watch RSS
- Dyve Biosciences, Inc. portfolio CI